Search / Trial NCT00002400

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Launched by PHARMACIA AND UPJOHN · Aug 30, 2001

Trial Information

Current as of December 27, 2024

Completed

Keywords

Hiv 1 Drug Therapy, Combination Zidovudine Hiv Protease Inhibitors Lamivudine Indinavir Rna, Viral Delavirdine Reverse Transcriptase Inhibitors

ClinConnect Summary

In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000 copies/ml or at the investigator's discretion.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV-1 positive.
  • CD4 count above 50.
  • HIV-1 RNA greater than 20,000.
  • Prior Medication:
  • Allowed:
  • Less than 1 month prior treatment with zidovudine.
  • Exclusion Criteria
  • Prior Medication:
  • Excluded:
  • Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
  • Prior ZDV of greater than 1 month total duration.
  • Prior Treatment:
  • Excluded:
  • Lamivudine.
  • Protease inhibitors.
  • Non-nucleoside reverse transcriptase inhibitors.

About Pharmacia And Upjohn

Pharmacia and Upjohn, a global biopharmaceutical company, specializes in the research, development, and commercialization of innovative therapies that address unmet medical needs across multiple therapeutic areas. With a strong commitment to advancing healthcare, the company leverages cutting-edge science and technology to improve patient outcomes. Pharmacia and Upjohn is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring the safety and efficacy of its products while fostering collaboration with healthcare professionals and regulatory authorities worldwide. Through its comprehensive portfolio, the company aims to enhance the quality of life for patients and contribute to the advancement of medical science.

Locations

Peapack, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials